key: cord-0961532-66lem44s authors: Angelis, V.; McFarlane, P.; Cunningham, N.; Gennatas, S.; Johnston, S.R.D.; Okines, A.; McGrath, S. title: 97P Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience date: 2021-05-31 journal: Annals of Oncology DOI: 10.1016/j.annonc.2021.03.111 sha: 98a0443926777dc0488a79fd6078eed7da94de8c doc_id: 961532 cord_uid: 66lem44s Background: CDK4-6 inhibitors are now considered the standard of care for advanced ER-positive HER2-negative advanced breast cancer (ABC) in combination with endocrine therapy (ET). During the first wave of the COVID-19 pandemic, clinicians were uncertain what impact CDK4-6 inhibitor-induced immunosuppression may have on the risk of contracting COVID-19 or the severity of infection. Some clinicians pre-emptively reduced doses, altered schedules, or even withheld treatment, continuing ET alone. There is currently no evidence that CDK4-6 inhibitors increase the risk or severity of COVID-19 infection, although there have reports of protracted illness. We describe our experience of 203 patients receiving CDK4-6 inhibitors during the first wave and demonstrate the safety of continuing treatment during this period. Methods: Epidemiological and clinical data were collected prospectively for patients at the Royal Marsden Hospital (RMH) and one network hospital with a ER-positive HER2-negative ABC that were receiving a CDK4-6 inhibitor between April 1st and June 30th 2020. Results: 200 patients received a CDK4-6 inhibitor in combination with ET, of which of 65/200 fulfilled local criteria to be screened with COVID-19 PCR testing and 6/65 were swab-positive. Two patients required hospital admission but there were no ICU admissions or COVID-19-associated deaths. Only 12 patients (6%) had treatment adjustments in the form of dose reduction (3/12), regime adjustment (2/12), or temporary interruption (7/12). In 9/12 cases this was a prophylactic measure due to additional risk factors;age (n=1), co-morbidities(n=3), patient choice (n=1) or overall concerns (n=4) to reduce the risk of contracting COVID-19. Results on dispensing >2 cycles at a time, telephone clinics, deferred CT scans and complications relating due to remote monitoring will also be reported. Conclusions: Based on this snapshot during the first wave of the COVID-19 pandemic, we conclude that continuation of CDK4-6 inhibitors appears safe. This project is helping to drive a UK-wide review of CDK4-6 inhibitor treatment continuation, adjustment during the pandemic, assessing the risk of acquiring clinically severe COVID-19 infection, and subsequent cancer-related outcomes for these patients. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: S.R.D. Johnston: Advisory/Consultancy: Eli Lilly;Advisory/Consultancy, Speaker Bureau/Expert testimony: AstraZeneca;Advisory/Consultancy, Research grant/Funding (institution): Puma Biotechnology;Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Pfizer;Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis;Speaker Bureau/Expert testimony: Eisai;Research grant/Funding (institution), Clinical Trials: Roche/Genentech;Research grant/Funding (institution), Clinical Trials: Eli Lilly;Research grant/Funding (institution), Clinical Trials: Pfizer;Research grant/Funding (institution), Clinical Trials: AstraZeneca;Research grant/Funding (institution), Clinical Trials: Novartis;Research grant/Funding (institution), Laboratory studies: Pfizer;Research grant/Funding (institution), Laboratory studies: Puma Biotechnology. A. Okines: Research grant/Funding (self): Pfizer;Honoraria (self): Leo Pharma;Speaker Bureau/Expert testimony: Seagen;Advisory/Consultancy: Roche;Research grant/Funding (self): Roche;Honoraria (self): AstraZeneca;Advisory/Consultancy: Seagen. S. McGrath: Speaker Bureau/Expert testimony: Pfizer. All other authors have declared no conflicts of interest. Myriad; Honoraria (self): Merck; Shareholder/Stockholder/Stock options, Cofounder/shareholder until 2016: Sividon diagnostics; Licensing/Royalties: VMScope digital pathology software; Licensing/ Royalties: WO2020109570A1 -cancer immunotherapy; Licensing/Royalties: WO2015114146A1 and WO2010076322A1-therapy response. S. Loibl: Honoraria (institution) , honoraria for lectures and ad boards paid to institute: AbbVie; Honoraria (institution), honoraria for lectures and ad boards paid to institute: Celgene; Honoraria (institution), honorarium for lectures paid to institute: PriME/Medscape; Honoraria (self), lecture: Chugai; Honoraria (self), Honoraria (institution) , honoraria paid to institute: Daiichi Sankyo; Honoraria (institution) , honorarium for ad boards paid to institute: Lilly; Honoraria (institution), advisor honorarium paid to institute: BMS; Honoraria (institution), advisor honorarium paid to institute: Puma; Honoraria (institution), paid to institute: Immunomedics; Honoraria (institution), honorarium for lectures and ad boards paid to institute: AstraZeneca; Honoraria (institution), honorarium for lectures and ad boards paid to institute: Pierre Fabre; Honoraria (institution), honorarium for lectures and ad boards paid to institute: Merck; Honoraria (institution), advisor honorarium paid to institute: EirGenix; Honoraria (institution), honorarium for lectures and ad boards paid to institute: Amgen; Honoraria (institution), honorarium for lectures and ad boards paid to institute: Novartis; Honoraria (institution), honorarium for lectures and ad boards paid to institute: Pfizer; Honoraria (institution), grant and honorarium paid to institute: Roche; Honoraria (institution), paid to institute: Seagen; Licensing/Royalties, Immunsignature in TNBC: EP14153692.0. V. Mueller: Advisory Background: ALP + fulvestrant is approved for PIK3CA-mutated, HR+/HER2e advanced BC in the US and EU. HG is an on-target adverse event (AE) of ALP and the most common all grade (G) and G3/4 AE in the phase III SOLAR-1 trial. Antihyperglycemic agents (AHAs) and ALP dose modifications (mods) and discontinuations (discs) were used to manage this AE (Table) . We present a pooled risk factor model using safety sets of the phase I X2101 (NCT01219699) and SOLAR-1 (NCT02437318) trials and its application to SOLAR-1 data. Methods: Pts (505) were randomly divided into training (405 pts) and testing sets (100 pts). Baseline factors for HG were identified, multiple models tested, and a random forest model was used to categorize pts as high or low risk for G3/4 HG based on 5 baseline factors (fasting plasma glucose [FPG] , BMI, HbA1c, monocyte counts, and age). Performance metrics will be presented. The training set identified G3/4 HG in 126/131 high (96.2%) vs 3/274 low risk (1.09%) pts, and was validated in the testing set with 20/33 high (60.6%) vs 12/67 low risk (17.9%) pts. A 2-month (mo) analysis of G3/4 HG risk confirmed decreased probability at lower risk scores (area under the curve: training set ¼ 0.991, testing set ¼ 0.767). In all pts in the ALP arm of SOLAR-1, the model found a higher incidence of all-G and G3/4 HG, use of multiple AHAs, and more dose mods and discs in the high vs low risk pts (Table) . There was no difference in median PFS in high (11.0 mo) vs low risk (10.9 mo) pts in the ALP arm with PIK3CA mutations. Background: CDK4-6 inhibitors are now considered the standard of care for advanced ER-positive HER2-negative advanced breast cancer (ABC) in combination with endocrine therapy (ET). During the first wave of the COVID-19 pandemic, clinicians were uncertain what impact CDK4-6 inhibitor-induced immunosuppression may have on the risk of contracting COVID-19 or the severity of infection. Some clinicians preemptively reduced doses, altered schedules, or even withheld treatment, continuing ET alone. There is currently no evidence that CDK4-6 inhibitors increase the risk or severity of COVID-19 infection, although there have reports of protracted illness. We describe our experience of 203 patients receiving CDK4-6 inhibitors during the first wave and demonstrate the safety of continuing treatment during this period. Methods: Epidemiological and clinical data were collected prospectively for patients at the Royal Marsden Hospital (RMH) and one network hospital with a ER-positive HER2-negative ABC that were receiving a CDK4-6 inhibitor between April 1st and June 30th 2020. Results: 200 patients received a CDK4-6 inhibitor in combination with ET, of which of 65/200 fulfilled local criteria to be screened with COVID-19 PCR testing and 6/65 were swab-positive. Two patients required hospital admission but there were no ICU admissions or COVID-19-associated deaths. Only 12 patients (6%) had treatment adjustments in the form of dose reduction (3/12), regime adjustment (2/12), or temporary interruption (7/12). In 9/12 cases this was a prophylactic measure due to additional risk factors; age (n¼1), co-morbidities(n¼3), patient choice (n¼1) or overall concerns (n¼4) to reduce the risk of contracting COVID-19. Results on dispensing >2 cycles at a time, telephone clinics, deferred CT scans and complications relating due to remote monitoring will also be reported. Conclusions: Based on this snapshot during the first wave of the COVID-19 pandemic, we conclude that continuation of CDK4-6 inhibitors appears safe. This project is helping to drive a UK-wide review of CDK4-6 inhibitor treatment continuation, adjustment during the pandemic, assessing the risk of acquiring clinically severe COVID-19 infection, and subsequent cancer-related outcomes for these patients. Legal entity responsible for the study: The authors. Funding: Has not received any funding. AVANTI (ML22452) assessed safety, effectiveness and pt-reported outcomes (EORTC QLQ-C30) with these regimens in German routine oncology practice. Methods: Eligible pts had HER2-negative aBC, no BEV contraindications and had received no prior CT for aBC. CT schedule, diagnostics and follow-up visits were at the physician's discretion. Data were collected for 1 y after starting BEV, then every 6 mo for 1.5 y (max follow-up: 2.5 y). Treatment satisfaction was rated by pts and physicians Median age was 60 y, 21% had TNBC, 56% prior (neo)adjuvant CT and 29% de novo metastatic disease. Pts receiving BEV + CAP were less likely to have de novo disease and more likely to have TNBC, age 60 y and prior CT and endocrine therapy (ET). The median treatment duration was 6.0 mo (95% CI 5.6e6.3) for BEV Grade 3/4 AEs were reported in 27% of pts and led to treatment discontinuation in 15%. Treatment satisfaction was rated as good or better by 304/394 (77%) responding pts at week 54 and in 1393/2065 pts (67%) by physicians across the study. Conclusions: Final results from AVANTI show median PFS of 12.6 mo and a safety profile consistent with phase III experience Legal entity responsible for the study Honoraria (self), Advisory/Consultancy: Amgen Advisory/ Consultancy: AstraZeneca Advisory/Consultancy, Travel/Accommodation/Expenses: Daiichi Sankyo Advisory/Consultancy: Eisai Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer Advisory/Consultancy: MSD Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche Advisory/Consultancy: Teva Advisory/Consultancy, Research grant/Funding (institution): Seattle Genetics Advisory/Consultancy: Genomic Health Advisory/Consultancy: Hexal Advisory/Consultancy: Pierre Fabre Advisory/Consultancy: ClinSol Advisory/Consultancy: Lilly Advisory/Consultancy: Tesaro; Honoraria (self), Advisory/Consultancy: Nektar Research grant/Funding (institution): Genentech. O. Hoffmann: Honoraria (self), Advisory/Consultancy: Roche; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Novartis Honoraria (self), Travel/Accommodation/Expenses: Pfizer Advisory/Consultancy, Travel/Accommodation/Expenses: MSD; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Daiichi Sankyo Honoraria (self): AstraZeneca; Honoraria (self), Travel/Accommodation/Expenses: Eisai Advisory/Consultancy, Travel/Accommodation/Expenses: Hexal. A-K. Sommer: Full/Part-time employment: Roche Pharma AG; Shareholder/Stockholder/Stock options: Roche. A. Schneeweiss: Honoraria (self), Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Honoraria (self) Research grant/Funding (institution), Travel/ Accommodation/Expenses: Celgene Honoraria (self), Travel/Accommodation/Expenses: Pfizer Honoraria (self): Novartis Honoraria (self): MSD Honoraria (self): Tesaro; Honoraria (self Research grant/Funding (institution): AbbVie. All other authors have declared no conflicts of interest 99P Analysis of ctDNA in advanced breast cancer reveals polyclonal disease associated with adverse outcome Addenbrooke's Hospital -Cambridge University Hospitals NHS Foundation Trust